Brodalumab at the ACR 2015 Meeting in San Francisco

There has been one publication on brodalumab at the ACR 2015 Annual Meeting in San Francisco.

Brodalumab is an anti-IL 17 receptor MAB, which is a promising new drug on the horizon against psoriatic arthritis as it targets IL-17, which plays a role "in the pathogenesis and ongoing inflammation of psoriatic disease". But only one study!

Mark C. Genovese and colleagues presented: “Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis”. Conclusion: “Treatment with brodalumab resulted in a safety profile comparable to the overall safety profile of biologics approved for PsA [psoriatic arthritis] and meaningful clinical benefit that was maintained through week 108 in patients with PsA in this ongoing OLE [open label extension].”

An evaluation of clinical data of phase 2 study isn’t very convincing. Where’s data on radiographic progression after two years? The sponsor doesn’t seem to push the agenda. Still committed or simply keeping it up at low level in case something weird happens to Secukinumab to push it from getting approval as a drug. Else I don’t see a reason, why not recruiting for a phase 3 study.

References:

Genovese MC, Mease PJ, Greenwald M, Ritchlin CT, Beaulieu A, Deodhar AA, Newmark R, Feng J, Erondu N, Nirula A. Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/two-year-clinical-response-to-brodalumab-an-anti-interleukin-17-receptor-antibody-in-patients-with-psoriatic-arthritis/. Accessed November 19, 2015.